Every 10-Q that NovoCure Limited (NVCR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NVCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NVCR filings page.
NovoCure Limited reported Q2 2026 net revenues of $183.6 million, up 16% year over year, and first‑half revenues of $357.6 million. Gross margin improved to 78%. Net loss narrowed to $15.7 million in Q2 and $86.8 million for the first half.
Cash, cash equivalents and short‑term investments totaled $440.6 million at June 30, 2026, against $200.0 million of senior secured term debt. Adjusted EBITDA turned positive at $10.8 million in Q2. Active patients on therapy rose to 5,128, driven mainly by Optune Gio.
During the period, the FDA approved Optune Pax for locally advanced pancreatic cancer and a CE certificate was obtained to market it in the EU. The METIS and PANOVA‑4 trials met key endpoints, while the TRIDENT trial in newly diagnosed GBM did not improve overall survival. The company notes it may need to raise additional capital as it expands indications.
NovoCure Limited reported higher revenue but a wider loss for the quarter ended March 31, 2026. Net revenues rose 12% to $174.1 million, driven mainly by international growth in Germany, France and other markets, plus increased U.S. usage of Optune Gio and Optune Lua.
Gross margin improved to 78% as cost per active patient fell, but operating expenses climbed on new indication launches and higher share-based compensation. The company recorded a net loss of $71.1 million, or $0.62 per share, compared with a $34.3 million loss a year earlier.
Adjusted EBITDA narrowed to a small loss of $0.3 million. Active patients on therapy increased to 4,791, supported by the U.S. launch of Optune Pax for locally advanced pancreatic cancer and ongoing expansion of Optune Lua for NSCLC. Cash, cash equivalents and short-term investments totaled $432.0 million, and 115,820,940 ordinary shares were outstanding as of April 24, 2026.
NovoCure Limited (NVCR) reported third-quarter 2025 results showing continued top-line growth alongside operating losses. Net revenues were $167,204 (thousands), up 8% year over year, driven by growth in France, Germany and other international markets, partially offset by lower U.S. prior-period claim benefits and $3,300 of FX tailwinds. Gross margin was 73% versus 77% a year ago, reflecting higher array costs, tariffs, and a $2,900 inventory obsolescence charge for Optune Lua arrays.
The company recorded a net loss of $37,270 (thousands) and operating loss of $36,021 (thousands). Cash and cash equivalents were $342,119 with short-term investments of $691,382 as of September 30, 2025. NovoCure drew the Tranche B term loan, bringing its senior secured credit facility borrowings to $200,000, and its 0% Convertible Senior Notes due 2025 carried a current liability of $560,620.
Commercial metrics improved: active patients rose to 4,416 from 4,113, and total prescriptions increased to 1,805 from 1,586. Management highlighted clinical and regulatory milestones, including PANOVA-3 results and ongoing PMA filings for pancreatic cancer (Optune Pax) and brain metastases from NSCLC (Optune Mya), while noting a potential impact from a U.S. government shutdown on FDA and reimbursement timelines.